Stayble initiates clinical phase 2b study in Spain

06 Oct 2020

Stayble Therapeutics today announced that the Company has initiated the first clinic in Spain for its clinical phase 2b study with the drug candidate STA363. Patient recruitment will commence immediately. The Company has now initiated clinics in all the three countries where it plans to conduct the study: the Netherlands, Russia and Spain. STA363 is intended for patients suffering from chronic disc-related low back pain.

CEO Andreas Gerward comments: COVID-19, and hence the access to healthcare services, has posed a challenge to us in our effort to initiate clinics. The fact that we now have initiated the first clinic in Spain and thus in all the countries planned for the study is something I am very proud of. I look forward to seeing additional clinics initiated. The treatment of the first patient in Spain will commence shortly. Meanwhile, we are monitoring the development of the COVID-19 situation closely, taking relevant measures to minimize its impact on the study. We are keeping to our overall timetable with regard to patient recruitment and implementation of the phase 2b study, despite a later start in Spain than originally scheduled.

The aim of the clinical phase 2b study is to demonstrate safety, tolerability and pain reduction following STA363 treatment. The level of pain is assessed using a numerical rating scale, 0-10, from no pain at all (0) to extreme pain (10). The patients will be followed for 12 months in order to get a better understanding of the long-term effects of STA363. The study will include approximately 100 patients and will be conducted in some twenty clinics in the Netherlands, Russia and Spain.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se

+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development, and is currently conducting a clinical phase 2b study is underway. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se